Bernstein initiated coverage of Avidity Biosciences with an Outperform rating and $50 price target The firm sees muscle as one of the most promising “next frontiers” for oligonucleotides, and says Avidity Biosciences (RNA) and Dyne (DYN) are “clear leaders in the space by virtue of their antibody-conjugated delivery tech.” Bernstein prefers shares of prefer Avidity, believing it has greater risk diversification with three drugs in pivotal trials, more conservative regulatory strategy in the large myotonic dystrophy type 1 indication, and a stronger balance sheet with cash runway into 2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity, BridgeBio, Coty, SAGE, Alkermes: Trending by Analysts
- Avidity Biosciences: Strong Market Position and Future Potential Justify Buy Rating
- Avidity Biosciences Positioned for Market Leadership with Promising DM1 Treatment in Phase 3 Trial
- Avidity Biosciences initiated with an Outperform at Wolfe Research
- Promising Developments in Avidity Biosciences’ FSHD Program Justify Buy Rating